---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-208975"
form_type: "8-K"
ticker: "TNYA"
cik: "0001858848"
company_name: "Tenaya Therapeutics, Inc."
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:55:22.532276+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tenaya reports Q1 net loss $19.3M, cash $80.9M; Alnylam deal; TN-201/401 data expected Q2 2026

## Summary
- Net loss $19.3M ($0.09/share) vs $26.9M ($0.24/share) in Q1 2025; cash $80.9M as of Mar 31, 2026.
- Alnylam collaboration: $10M upfront, up to $1.1B milestones; cash runway into H2 2027 inclusive of upfront.
- TN-201 (HCM gene therapy): interim Cohort 2 data and Cohort 1 update expected Q2 2026; enrollment resumed after protocol amendments.
- TN-401 (ARVC gene therapy): one-year Cohort 1 and initial Cohort 2 data to be presented at ASGCT May 15, 2026.
- TN-301 (HDAC6i) granted Rare Pediatric and Orphan Drug Designation for DMD; preclinical data showed improved grip strength.

## SEC filing metadata
- accession: 0001193125-26-208975
- form_type: 8-K
- ticker: TNYA
- cik: 0001858848
- company_name: Tenaya Therapeutics, Inc.
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858848/000119312526208975/0001193125-26-208975-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858848/000119312526208975/tnya-20260506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-208975
- JSON: https://secwatch.observer/filing/0001193125-26-208975.json
- Plain text: https://secwatch.observer/filing/0001193125-26-208975.txt

## Source-grounded claims
- claim_id: 325832b3d3682736e202dd23518a6791b762d286
  claim: Tenaya Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2026.
  evidence_excerpt: On May 6, 2026, Tenaya Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1858848/000119312526208975/0001193125-26-208975-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.